Literature DB >> 32270884

Role of nonstructural proteins in the pathogenesis of SARS-CoV-2.

Severino Jefferson Ribeiro da Silva1, Caroline Targino Alves da Silva1, Renata Pessôa Germano Mendes1, Lindomar Pena1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32270884      PMCID: PMC7262198          DOI: 10.1002/jmv.25858

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
To the Editor, We read with great interest the study authored by Angeletti et al regarding the role of nonstructural proteins nsp2 and nsp3 in the pathogenesis of coronavirus disease 2019 (COVID‐19). COVID‐19 emerged in December 2019 in Wuhan City, Hubei Province, China and is caused by a novel viral variant belonging to the viral variant belonging to the severe acute respiratory syndrome‐related coronavirus (SARS‐rCoV) species of subgenus Sarbecovirus, genus Betacoronavirus, family Coronaviridae and named SARS‐CoV‐2.  The novel SARS‐CoV‐2 virus shows the typical genome organization of the betacoronaviruses, which consists of a 5′‐untranslated region (5′‐UTR), replicase complex (orf1ab), S gene, E gene, M gene, N gene, 3′‐UTR, and other open reading frames (ORFs) yet to be characterized. In addition to SARS‐CoV‐2, this genus has other two highly pathogenic CoVs: the SARS‐CoV and the Middle East respiratory syndrome CoV (MERS‐CoV). All three viruses are originated from bats and have emerged in the 21st century causing outbreaks with high mortality rates. SARS‐CoV and MERS‐CoV infection results in higher mortality rates compared to SARS‐CoV‐2, but only the latter was capable to establishing sustained human‐to human‐transmission. In their article, the authors used several computational tools to analyze the ORF1a and ORF1b of SARS‐CoV‐2. The ORF1a/b comprise about two‐thirds of the viral genome and codes for 16 nonstructural proteins (nsp1‐16). There is a −1 frameshift between ORF1a and ORF1b, leading to production of two polypeptides (pp1a and pp1ab), which are further processed by viral‐encoded proteases into 16 nsp. They found a segment within the nsp2 and the nsp3 regions that has no homology with other CoVs and suggested that “the stabilizing mutation falling in the endosome‐associated‐protein‐like domain of the nsp2 protein could account for COVID‐2019 high ability of contagious, while the destabilizing mutation in nsp3 proteins could suggest a potential mechanism differentiating COVID‐2019 from SARS.” The work is of unquestionable value, but we would like to make some important considerations from a molecular virology point of view. First, according to the International Committee on Taxonomy of Viruses the correct nomenclature for the novel coronavirus is SARS‐CoV‐2 and not COVID‐2019 as written by the authors. The virus is the etiological agent of the disease named by WHO as “coronavirus disease 2019” (abbreviated “COVID‐19”). Second, phenotypic inference from sequence information alone can lead to wrong conclusions. Viral pathogenesis is usually a polygenic trait, even though some specific mutations can have a great impact by themselves. As an example, a highly pathogenic porcine reproductive and respiratory syndrome virus (PRRSV) emerged in China in 2006 causing a widespread outbreak of disease in pigs that was very atypical. Initially, the unusual high pathogenicity of this novel PRRSV strain was associated with a unique 30‐amino‐acid deletion in its Nsp2 protein. However, subsequent studies using reverse genetics found that this large genomic deletion was not responsible to PRRSV virulence.  Actually, the increased virulence of this PRRSV strain was mapped to the Nsp9 and Nsp10 proteins. Mutations are also context‐dependent. The PB1‐F2 protein of influenza A viruses (IAV) has been reported as an important virulence factor and the N66S polymorphism in this protein played a role in the high lethality of the 1918 and other IAV. Pena and coworkers used reverse genetics to study the role of PB1‐F2 (and the N66S mutation) in the virulence of different IAV and demonstrated that their effects and were host and strain‐dependent and ranged from higher virulence, no phenotype, and even lower virulence. , , Identification of molecular markers of SARS‐CoV‐2 virulence, host range, and transmissibility can be accomplished unequivocally by reverse genetics (Figure 1). This powerful technique involves the generation of an infectious virus from a cloned full‐length complementary DNA and evaluation of the role of specific genes (and mutations) in adequate cell culture systems and animal models. Although the large genome of CoVs and its instability in bacterial plasmid vectors creates difficulties in the construction of reverse genetics systems, many technological advances have allowed the successful engineering of several CoVs, including SARS‐CoV and MERS‐CoV. The development of reverse genetics systems for SARS‐CoV‐2 will shed light on many aspects of its biology and will pave the way to the development of vaccines and antivirals against this lethal pathogen.
Figure 1

Schematic representation of forward and reverse genetic approaches. Forward genetics aims to identify the viral genotype that is responsible for a specific phenotype, whereas reverse genetic techniques enable the generation of an infectious virus from a cloned full‐length genome and the subsequent studies of the phenotypic effects of specific gene sequences in a biological system. Relevant animal models can used to study viral phenotypes, including virulence and transmissibility. ORF, open reading frame; SAR‐CoV‐2, Severe acute respiratory syndrome‐coronavirus 2

Schematic representation of forward and reverse genetic approaches. Forward genetics aims to identify the viral genotype that is responsible for a specific phenotype, whereas reverse genetic techniques enable the generation of an infectious virus from a cloned full‐length genome and the subsequent studies of the phenotypic effects of specific gene sequences in a biological system. Relevant animal models can used to study viral phenotypes, including virulence and transmissibility. ORF, open reading frame; SAR‐CoV‐2, Severe acute respiratory syndrome‐coronavirus 2

CONFLICT OF INTERESTS

The author declares that there are no conflict of interests.
  9 in total

1.  Restored PB1-F2 in the 2009 pandemic H1N1 influenza virus has minimal effects in swine.

Authors:  Lindomar Pena; Amy L Vincent; Crystal L Loving; Jamie N Henningson; Kelly M Lager; Alessio Lorusso; Daniel R Perez
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

2.  Strain-dependent effects of PB1-F2 of triple-reassortant H3N2 influenza viruses in swine.

Authors:  Lindomar Pena; Amy L Vincent; Crystal L Loving; Jamie N Henningson; Kelly M Lager; Weizhong Li; Daniel R Perez
Journal:  J Gen Virol       Date:  2012-07-18       Impact factor: 3.891

3.  Novel coronavirus (SARS-CoV-2) epidemic: a veterinary perspective.

Authors:  Alessio Lorusso; Paolo Calistri; Antonio Petrini; Giovanni Savini; Nicola Decaro
Journal:  Vet Ital       Date:  2020-04-24       Impact factor: 1.101

4.  The 30-amino-acid deletion in the Nsp2 of highly pathogenic porcine reproductive and respiratory syndrome virus emerging in China is not related to its virulence.

Authors:  Lei Zhou; Jialong Zhang; Jingwen Zeng; Shuoyan Yin; Yanhua Li; Linying Zheng; Xin Guo; Xinna Ge; Hanchun Yang
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

5.  Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species.

Authors:  Mirco Schmolke; Balaji Manicassamy; Lindomar Pena; Troy Sutton; Rong Hai; Zsuzsanna T Varga; Benjamin G Hale; John Steel; Daniel R Pérez; Adolfo García-Sastre
Journal:  PLoS Pathog       Date:  2011-08-11       Impact factor: 6.823

6.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.

Authors: 
Journal:  Nat Microbiol       Date:  2020-03-02       Impact factor: 17.745

7.  Nsp9 and Nsp10 contribute to the fatal virulence of highly pathogenic porcine reproductive and respiratory syndrome virus emerging in China.

Authors:  Yan Li; Lei Zhou; Jialong Zhang; Xinna Ge; Rong Zhou; Huaguo Zheng; Gang Geng; Xin Guo; Hanchun Yang
Journal:  PLoS Pathog       Date:  2014-07-03       Impact factor: 6.823

Review 8.  Coronavirus reverse genetic systems: infectious clones and replicons.

Authors:  Fernando Almazán; Isabel Sola; Sonia Zuñiga; Silvia Marquez-Jurado; Lucia Morales; Martina Becares; Luis Enjuanes
Journal:  Virus Res       Date:  2014-06-12       Impact factor: 3.303

9.  COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis.

Authors:  Silvia Angeletti; Domenico Benvenuto; Martina Bianchi; Marta Giovanetti; Stefano Pascarella; Massimo Ciccozzi
Journal:  J Med Virol       Date:  2020-02-28       Impact factor: 2.327

  9 in total
  24 in total

Review 1.  Two Years into the COVID-19 Pandemic: Lessons Learned.

Authors:  Severino Jefferson Ribeiro da Silva; Jessica Catarine Frutuoso do Nascimento; Renata Pessôa Germano Mendes; Klarissa Miranda Guarines; Caroline Targino Alves da Silva; Poliana Gomes da Silva; Jurandy Júnior Ferraz de Magalhães; Justin R J Vigar; Abelardo Silva-Júnior; Alain Kohl; Keith Pardee; Lindomar Pena
Journal:  ACS Infect Dis       Date:  2022-08-08       Impact factor: 5.578

2.  Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach.

Authors:  Gustavo Obando-Pereda
Journal:  J Med Virol       Date:  2021-06-11       Impact factor: 20.693

3.  Update on the target structures of SARS-CoV-2: A systematic review.

Authors:  Manisha Prajapat; Phulen Sarma; Nishant Shekhar; Ajay Prakash; Pramod Avti; Anusuya Bhattacharyya; Hardeep Kaur; Subodh Kumar; Seema Bansal; Amit Raj Sharma; Bikash Medhi
Journal:  Indian J Pharmacol       Date:  2020-06-03       Impact factor: 1.200

4.  Nature's therapy for COVID-19: Targeting the vital non-structural proteins (NSP) from SARS-CoV-2 with phytochemicals from Indian medicinal plants.

Authors:  Pratap Kumar Parida; Dipak Paul; Debamitra Chakravorty
Journal:  Phytomed Plus       Date:  2020-11-27

Review 5.  Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update.

Authors:  Shikha Thakur; Bibekananda Sarkar; Arshad J Ansari; Akanksha Khandelwal; Anil Arya; Ramarao Poduri; Gaurav Joshi
Journal:  Food Chem Toxicol       Date:  2020-11-27       Impact factor: 6.023

Review 6.  Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development.

Authors:  Fouad A Abolaban; Fathi M Djouider
Journal:  Open Life Sci       Date:  2021-06-02       Impact factor: 0.938

7.  Temporal landscape of mutational frequencies in SARS-CoV-2 genomes of Bangladesh: possible implications from the ongoing outbreak in Bangladesh.

Authors:  Otun Saha; Israt Islam; Rokaiya Nurani Shatadru; Nadira Naznin Rakhi; Md Shahadat Hossain; Md Mizanur Rahaman
Journal:  Virus Genes       Date:  2021-07-12       Impact factor: 2.332

8.  Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil.

Authors:  Severino Jefferson Ribeiro da Silva; Lindomar Pena
Journal:  One Health       Date:  2021-06-29

9.  Response to Ribeiro da Silva et al,"Role of nonstructural proteins in the pathogenesis of SARS-CoV-2".

Authors:  Massimo Ciccozzi; Domenico Benvenuto; Marta Giovanetti; Martina Bianchi; Stefano Pascarella; Silvia Angeletti
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

Review 10.  COVID-19 Vaccine: A comprehensive status report.

Authors:  Simran Preet Kaur; Vandana Gupta
Journal:  Virus Res       Date:  2020-08-13       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.